ERBB2 and inflammatory breast carcinoma: In HER2+ IBC completely treated with trastuzumab and chemotherapy, anti-HER2 TH1 immune responsivity independently correlates with disease recurrence and is mediated by anti-HER2 CD4+T-bet+IFN-γ+ (TH1) phenotypes but not CD4+GATA-3+IFN-γ+ (TH2) or CD4+CD25+FoxP3+ (Treg) response (163).